You just read:

Novartis submits application to FDA for Kymriah™ (tisagenlecleucel) in adult patients with r/r DLBCL, seeking second indication for first-ever FDA approved CAR-T therapy

News provided by

Novartis

Oct 31, 2017, 02:23 ET